Skip to main content
. 2011 Jul;79(7):2681–2689. doi: 10.1128/IAI.00009-11

Fig. 1.

Fig. 1.

Schematic representation of glycan structures from isolates from GBS patients and the cst-II KO mutant. (A) GB11 and GB2, containing terminal α2,3-linked sialic acid and the corresponding ganglioside GD1a mimic. (B) GB16 and GB19, containing terminal α2,8-linked sialic acid and the corresponding ganglioside GD1c mimic. (C) Cst-II KO, GB2 Cst-II KO, and GB19 neuraminidase, lacking sialic acid.